Translating advances from the basic biology of aging into clinical application

Research output: Contribution to journalReview articlepeer-review

75 Scopus citations


Recently, lifespan and healthspan have been extended in experimental animals using interventions that are potentially translatable into humans. A great deal of thought and work is needed beyond the usual steps in drug development to advance these findings into clinical application. Realistic pre-clinical and clinical trial paradigms need to be devised. Focusing on subjects with symptoms of age-related diseases or frailty or who are at imminent risk of developing these problems, measuring effects on short-term, clinically relevant outcomes, as opposed to long-term outcomes such as healthspan or lifespan, and developing biomarkers and outcome measures acceptable to regulatory agencies will be important. Research funding is a major roadblock, as is lack of investigators with combined expertise in the basic biology of aging, clinical geriatrics, and conducting investigational new drug clinical trials. Options are reviewed for developing a path from the bench to the bedside for interventions that target fundamental aging processes.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalExperimental Gerontology
Issue number1
StatePublished - Jan 2013


  • Age-related disease
  • Aging
  • Cellular senescence
  • Frailty
  • Translation

ASJC Scopus subject areas

  • Biochemistry
  • Aging
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Cell Biology


Dive into the research topics of 'Translating advances from the basic biology of aging into clinical application'. Together they form a unique fingerprint.

Cite this